

September 12, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:

**“Strides Shasun receives USFDA Approval
for Potassium Citrate Extended-Release Tablets”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary





Press Release

September 12, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

**Strides Shasun receives USFDA Approval
for Potassium Citrate Extended-Release Tablets**

**First approval for an Extended Release product
Product to be launched immediately**

Bangalore, September 12, 2017 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for ***Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq, and 15 mEq***

According to IMS data, the US market for Potassium Citrate is approximately USD 110 Million. Strides Shasun will be the second generic player to commercialize the product.

The product, which is the first approval for an Extended Release tablet for the Company, will be launched immediately.


About Potassium Citrate Extended Release Tablets

Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals

Extended release pill is formulated in such a way that the drug is released slowly over time. This has the advantage of taking pills less often and fewer side effects, as the levels of the drug in the body are more consistent.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.



The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u> Shashank Sinha, Managing Director +91 80 6784 0335 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com K Priya: +91 95354 25418 priya@fortunapr.com
--	--

